Renal Cell Carcinoma (RCC) Clinical Trials

Find Renal Cell Carcinoma (RCC) Clinical Trials Near You

Identification and Description of Patients With High-risk Non Metastatic RCC (UroCCR 127)

Status: Recruiting

Location: See location...

Intervention Type: Other

Study Type: Observational

SUMMARY

Renal cell carcinoma (RCC) is the 14th most common cancer worldwide. Surgery is the standard of care for localized RCC, however, the risk of recurrence varies widely among patients. Adjuvant pembrolizumab has been shown to improve outcomes after nephrectomy but is associated with substantial toxicity and high costs. This study uses real-world data from the French UroCCR-Chain registry to characterize the natural history, management, and outcomes of non-metastatic RCC in France, with the aim of informing adjuvant treatment decisions

Eligibility

Participation Requirements

Sex: All

Minimum Age: 18

Healthy Volunteers: f

View:

• Adult patients diagnosed with local RCC or high-risk locally advanced RCC,

• Included in UroCCR register between 1st january 2014 and 31st december 2023,

• Consenting to participate in UroCCR and UroCCR-Chain registers.

Locations

Other Locations

France

CHU Bordeaux

RECRUITING

Bordeaux

Contact Information

Primary

Jean-Christophe BERNHARD, Pr

jean-christophe.bernhard@chu-bordeaux.fr

0033540451179

Backup

Gaelle MARGUE, Dr

Time Frame

Start Date: 2026-04-17

Estimated Completion Date: 2028-04-17

Participants

Target number of participants: 6109

Treatments

Overall RCC population

Patients diagnosed with local RCC or high-risk locally advanced RCC.

Non clear RCC population

Clear RCC population stratified by eligibility based on the Keynote-564 study criteria

Keynote-564 study criteria: pT2 grade 4, pT3-T4 with any N and any grade, any T with N1, all M0

Related Therapeutic Areas

Renal Cell Carcinoma (RCC)

Nephrectomy

Similar Clinical Trials

View All